Page last updated: 2024-09-04

glucagon and semaglutide

glucagon has been researched along with semaglutide in 3 studies

Compound Research Comparison

Studies (glucagon)	Trials (glucagon)	Recent Studies (post-2010) (glucagon)	Studies (semaglutide)	Trials (semaglutide)	Recent Studies (post-2010) (semaglutide)
26,039	1,498	3,054	574	101	559

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Eckel, RH; Koh, KK; Lim, S	1
Strey, C	1
Coskun, T; DeVries, JH; Haupt, A; Heise, T; Li, J; Mari, A; Mather, KJ; Milicevic, Z; Pratt, EJ; Thomas, MK; Urva, S	1

Reviews

2 review(s) available for glucagon and semaglutide

Article	Year
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. Atherosclerosis, 2018, Volume: 272 Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2018
[Technological Innovations in Diabetes Therapy]. Praxis, 2018, Volume: 107, Issue:19 Topics: Administration, Oral; Blood Glucose Self-Monitoring; Clinical Trials, Phase III as Topic; Diabetes Mellitus; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Insulin; Insulin Infusion Systems; Inventions; Pancreas, Artificial	2018

Article

Year

Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.

Atherosclerosis, 2018, Volume: 272

Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2018

[Technological Innovations in Diabetes Therapy].

Praxis, 2018, Volume: 107, Issue:19

Topics: Administration, Oral; Blood Glucose Self-Monitoring; Clinical Trials, Phase III as Topic; Diabetes Mellitus; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Insulin; Insulin Infusion Systems; Inventions; Pancreas, Artificial

2018

Trials

1 trial(s) available for glucagon and semaglutide

Article	Year
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. The lancet. Diabetes & endocrinology, 2022, Volume: 10, Issue:6 Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulins; Islets of Langerhans; Treatment Outcome	2022

Article

Year

Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.

The lancet. Diabetes & endocrinology, 2022, Volume: 10, Issue:6

Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulins; Islets of Langerhans; Treatment Outcome

2022